ANVS Jul 2024 27.500 call
| Previous close | 0.3000 |
| Open | 0.6000 |
| Bid | 0.0500 |
| Ask | 1.9000 |
| Strike | 27.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.3000 - 0.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 106 |
GlobeNewswireAnnovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results. Clinical Updates AD Phase II/III Study On April 29, Annovis announced statistically significant Phase II/III data in patients with early Alzheimer’s disease (AD). Significantly higher rate of improveme
ZacksAmicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
ZacksXenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
